Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): A prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion

Retina

Volumn 29, Issue 7, 2009, Pages 932-940

  Hattenbach, Lars Olof ^a,f   Arndt, Carl Friedrich ^b   Lerche, Ralf ^c   Scharrer, Inge ^a   Baatz, Holger ^a   Margaron, Fabrice ^d   Richard, Gisbert ^c   Behrens Baumann, Wolfgang ^e   Ohrloff, Christian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Hemodilution; Recombinant tissue plasminogen activator; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; HETASTARCH; PENTOXIFYLLINE; SALICYLIC ACID;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEMATOMA; HEMODILUTION; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 68249089451     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a3b870     Document Type: Article

References (38)

1. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990;110:118-123. (Pubitemid 20242332)
2. Mason J III, Feist R, White M Jr, Swanner J, McGwin G Jr, Emond T. Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 2004;111:540-545. (Pubitemid 38293113)
3. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006;26:297-305.
4. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001;108:2249-2257.
5. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 2004;24:348-355. (Pubitemid 38780461)
6. Barak A, Kesler A, Gold D, Loewenstein A. Visual field defects after radial optic neurotomy for central retinal vein occlusion. Retina 2006;26:549-554. (Pubitemid 44620397)
7. Feltgen N, Junker B, Agostini H, Hansen LL. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology 2007;114:716-723. (Pubitemid 46483678)
8. Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465-472. (Pubitemid 351354949)
9. Cekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25:846-850. (Pubitemid 41456574)
10. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284. (Pubitemid 44318180)
11. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008; 351-355.
12. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27:1004-1012. (Pubitemid 350303999)
13. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion - results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436. (Pubitemid 47423323)
14. Vannas S, Raitta C. Anticoagulant treatment of retinal venous occlusion. Am J Ophthalmol 1966;62:874-884.
15. Schmetterer L, Kemmler D, Breiteneder H, et al. A randomized, placebo-controlled, double-blind, crossover study of the effect of pentoxifylline on ocular fundus pulsations. Am J Ophthalmol 1996;121:169-176. (Pubitemid 26055161)
16. Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989;73:895-899. (Pubitemid 20004003)
17. Chen HC, Wiek J, Gupta A, Luckie A, Kohner EM. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998;82:162-167. (Pubitemid 28176992)
18. Hattenbach LO, Steinkamp GWK, Scharrer I, Ohrloff C. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212:394-398. (Pubitemid 28446596)
19. Hattenbach LO, Wellermann G, Steinkamp GW, Scharrer I, Koch FH, Ohrloff C. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica 1999;213:360-366. (Pubitemid 29524922)
20. Kohner EM, Pettit JE, Hamilton AM. Streptokinase in central retinal vein occlusion: a controlled clinical trial. BMJ 1976;1:550-553.
21. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996;94:471-504. (Pubitemid 26406044)
22. Costen MT, Donaldson WB, Olson JA. Acute central retinal vein occlusion successfully treated with intravenous thrombolysis. Br J Ophthalmol 1999;83:1196-1197. (Pubitemid 29469132)
23. Paques M, Vallee JM, Herbreteau D, et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol 2000;84:1387-1391.
24. Sloan M, Gore JM. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am J Cardiol 1992;69: 21A-38A.
25. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
26. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronaryartery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
27. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150.
28. Brott TG, Haley EC Jr, Levy DE. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-640.
29. Haley EC Jr, Levy DE, Brott TG. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
30. Kolbel T, Lindh M, Holst J, et al. Extensive acute deep vein thrombosis of the iliocaval segment: midterm results of thrombolysis and stent placement. J Vasc Interv Radiol 2007;18:243-250. (Pubitemid 46616688)
31. Ouriel K, Veith FJ, Sasahara AA. Comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998;338:1105-1111.
32. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: A prospective histopathologic study of 29 eyes in 28 cases. Retina 1981;1:27-55.
33. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:163-168. (Pubitemid 36097051)
34. Cho YP, Jang HJ, Lee DH, et al. Deep venous thrombosis associated with protein C and/or S deficiency: management with catheter-directed thrombolysis. 7 2003;76:380-384.
35. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 2000;84:609-613. (Pubitemid 30339312)
36. Tsaloumas MD, Kirwan J, Vinall H, et al. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 2000;14:821-827. (Pubitemid 32007785)
37. Anderson JL, Karagounis L, Allan A, Bradford MJ, Menlove RL, Pryor TA. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991;68:166-170.
38. Suri MF, Nasar A, Hussein HM, Divani AA, Qureshi AI. Intra-arterial thrombolysis for central retinal artery occlusion in the United States: Nationwide In-patient Survey 2001-2003. J Neuroimaging 2007;17:339-343.